Download PDF
Hamostaseologie 2018; 38(02): 106-111
DOI: 10.5482/HAMO-16-12-0046
Case report
Schattauer GmbH Stuttgart

Acute Transmural Myocardial Infarction by Coronary Embolism in a Patient with JAK2 V617F-Positive Essential Thrombocythemia

Johannes Rotta detto Loria
1   Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany
,
Justyna Rawluk
2   Department of Hematology and Oncology, Medical Centre – University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
,
Tobias Krauss
3   Department of Radiology, Medical Centre – University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
,
Christoph Bode
1   Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany
,
Martin Moser
1   Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany
,
Thomas Helbing
1   Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany
› Author Affiliations
Further Information

Publication History

14 December 2016

10 July 2017

Publication Date:
29 May 2018 (online)

Also available at
   Permissions and Reprints

Essential thrombocythemia (ET) is an acquired myeloproliferative disorder which results from malignant transformation of a multipotent hematopoietic progenitor cell. The disease is characterized by platelet count elevation (> 450 000 /µl) and augmented platelet reactivity causing thrombotic events and haemorrhages. The etiology of bleeding in ET is multifactorial and includes among others an acquired von Willebrand syndrome especially in the presence of extreme thrombocytosis (> 1 000 000 /µl). Thromboses can occur in arterial and venous vessels and are far more frequent than bleeding. Thrombotic complications are the major cause of morbidity and mortality in ET patients and do not correlate with platelet count.[1]

Herein, we report the case of a 53-year old man with low cardiovascular risk profile and untreated ET presenting with a transmural myocardial infarction (STEMI) in the territory of the left anterior descending and the right coronary artery most likely due to multiple coronary embolisation.

 

  • References

  • 1 Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 2015; 90 (02) 162-173
    CrossrefPubMedGoogle Scholar
  • 2 Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol 2006; 47 (8 Suppl): C7-12
    CrossrefPubMedGoogle Scholar
  • 3 Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33 (20) 2569-2619
    CrossrefPubMedGoogle Scholar
  • 4 Mahmoud A, Saad M, Elgendy YI. Simultaneous multi-vessel coronary thrombosis in patients with ST-elevation myocardial infarction: a systematic review. Cardiovasc Revasc Med 2015; 16 (03) 163-166
    CrossrefPubMedGoogle Scholar
  • 5 Roule V, Sabatier R, Lognoné T. , et al. Thrombus in normal coronary arteries: retrospective study and review of case reports. Arch Cardiovasc Dis 2011; 104 (04) 216-226
    CrossrefPubMedGoogle Scholar
  • 6 Carobbio A, Thiele J, Passamonti F. , et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011; 117 (22) 5857-5859
    CrossrefPubMedGoogle Scholar
  • 7 Landolfi R, Di Gennaro L. Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica 2008; 93 (03) 331-335
    CrossrefPubMedGoogle Scholar
  • 8 Hobbs CM, Manning H, Bennett C. , et al. JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood 2013; 122 (23) 3787-3797
    CrossrefPubMedGoogle Scholar
  • 9 Fleischman AG, Tyner JW. Causal role for JAK2 V617F in thrombosis. Blood 2013; 122 (23) 3705-3706
    CrossrefPubMedGoogle Scholar
  • 10 Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood 2013; 122 (13) 2176-2184
    CrossrefPubMedGoogle Scholar
  • 11 Pascale S, Petrucci G, Dragani A. , et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012; 119 (15) 3595-3603
    CrossrefPubMedGoogle Scholar
  • 12 Beer PA, Erber WN, Campbell PJ, Green AR. How I treat essential thrombocythemia. Blood 2011; 117 (05) 1472-1482
    CrossrefPubMedGoogle Scholar
  • 13 Björkholm M, Hultcrantz M, Derolf ÅR. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?. Best Pract Res Clin Haematol 2014; 27 (02) 141-153
    CrossrefPubMedGoogle Scholar
  • 14 Pai SG, Kaplan JB, Giles FJ. Long-acting interferon for myeloproliferative neoplasms – an update. Expert Rev Hematol 2016; 9 (10) 915-917
    CrossrefPubMedGoogle Scholar
  • 15 Kovacsovics-Bankowski M, Kelley TW, Efimova O. , et al. Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2(V617F) allelic burden. Exp Hematol Oncol 2015; 5: 28
    CrossrefPubMedGoogle Scholar
  • 16 Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008; 22 (11) 1990-1998
    CrossrefPubMedGoogle Scholar
  • 17 Kiladjian JJ, Cassinat B, Chevret S. , et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112 (08) 3065-3072
    CrossrefPubMedGoogle Scholar
  • 18 Besses C, Alvarez-Larrán A. How to Treat Essential Thrombocythemia and Polycythemia Vera. Clin Lymphoma Myeloma Leuk 2016; 16 (Suppl): S114-S123
    CrossrefPubMedGoogle Scholar
  • 19 Hamada Y, Matsuda Y, Fujii B. , et al. Multiple coronary thrombosis in a patient with thrombocytosis. Clin Cardiol 1989; 12 (12) 723-724
    CrossrefPubMedGoogle Scholar
  • 20 Michaels AD, Whisenant B, MacGregor JS. Multivessel coronary thrombosis treated with abciximab (ReoPro) in a patient with essential thrombocythemia. Clin Cardiol 1998; 21 (02) 134-138
    CrossrefPubMedGoogle Scholar
  • 21 Terada H, Satoh H, Uehara A. Multivessel coronary thrombosis, acute myocardial infarction, and no reflow in a patient with essential thrombocythaemia. Heart 2000; 83 (06) E10
    CrossrefPubMedGoogle Scholar
  • 22 Ozben B, Ekmekci A, Bugra Z. , et al. Multiple coronary thrombosis and stent implantation to the subtotally occluded right renal artery in a patient with essential thrombocytosis: a case report with review. J Thromb Thrombolysis 2006; 22 (01) 79-84
    CrossrefPubMedGoogle Scholar
  • 23 Niccoli G, Scalone G, Crea F. Acute myocardial infarction with no obstructive coronary atherosclerosis: mechanisms and management. Eur Heart J 2015; 36 (08) 475-481
    CrossrefPubMedGoogle Scholar
  • 24 Nader RG, Barr F, Rubin R. , et al. Aortic degenerative changes and thrombus formation: an unusual cause of massive myocardial infarction with normal coronary arteries. Am J Med 1989; 86 (6 Pt 1): 718-722
    CrossrefPubMedGoogle Scholar
  • 25 Ito H, Takahashi K, Sasaki H. , et al. Large thrombus in the ascending aorta successfully treated by thrombolysis – an unusual cause of acute massive myocardial infarction. Jpn Circ J 2001; 65 (06) 572-574
    CrossrefPubMedGoogle Scholar
  • 26 Knoess M, Otto M, Kracht T, Neis P. Two consecutive fatal cases of acute myocardial infarction caused by free floating thrombus in the ascending aorta and review of literature. Forensic Sci Int 2007; 171 (01) 78-83
    CrossrefPubMedGoogle Scholar
  • 27 Oki M, Moriuchi M, Kawada H. , et al. A case of essential thrombocythemia presenting with aortic thrombosis. Tokai J Exp Clin Med 2008; 33 (04) 135-137
    PubMedGoogle Scholar
  • 28 Morata Barrado PC, Blanco Cañibano E, García Fresnillo B, Guerra Requena M. Acute lower limb ischemia in a patient with aortic thrombus and essential thrombocytosis. Int J Hematol 2009; 90 (03) 343-346
    CrossrefPubMedGoogle Scholar
  • 29 Lorelli DR, Shepard AD. Aortic mural thrombus embolization: an unusual presentation of essential thrombocytosis. Ann Vasc Surg 2002; 16 (03) 375-379
    CrossrefPubMedGoogle Scholar
  • 30 Bachmeyer C, Elalamy I. [Aortic thrombus and splenic infarcts indicating essential thrombocythemia]. Rev Med Intern 2011; 32 (09) e102-104
    CrossrefPubMedGoogle Scholar
  • 31 Hino H, Terasaki T, Hashimoto Y. , et al. [Cerebral infarction associated with mobile thoracic ascending aortic thrombus in a patient with essential thrombocythemia]. Rinsho Shinkeigaku 1999; 39 (07) 705-710
    PubMedGoogle Scholar
  • 32 Fang M, Agha S, Lockridge L. , et al. Medical management of a large aortic thrombus in a young woman with essential thrombocythemia. Mayo Clin Proc 2001; 76 (04) 427-431
    CrossrefPubMedGoogle Scholar
  • 33 Sohn V, Arthurs Z, Andersen C, Starnes B. Aortic thrombus due to essential thrombocytosis: strategies for medical and surgical management. Ann Vasc Surg 2008; 22 (05) 676-680
    CrossrefPubMedGoogle Scholar
  • 34 Johnson M, Gernsheimer T, Johansen K. Essential thrombocytosis: underemphasized cause of large-vessel thrombosis. J Vasc Surg 1995; 22 (04) 443-449
    CrossrefPubMedGoogle Scholar
  • 35 Campos Franco J, Martínez Lesquereux L, Seoane Pose C, Pazos González G. [Aortic thrombosis in a patient with essential thrombocythemia]. Cir Esp 2013; 91 (02) e9
    CrossrefPubMedGoogle Scholar
  • 36 Choukroun EM, Labrousse LM, Madonna FP, Deville C. Mobile thrombus of the thoracic aorta: diagnosis and treatment in 9 cases. Ann Vasc Surg 2002; 16 (06) 714-722
    CrossrefPubMedGoogle Scholar
  • 37 Böckler D, von Tengg-Kobligk H, Schoebinger M. , et al. An unusual cause of peripheral artery embolism: floating thrombus of the thoracic aorta surgically removed. VASA 2007; 36 (02) 121-123
    CrossrefPubMedGoogle Scholar
  • 38 Wachsman DE, Jacobs AK. Paradoxical coronary embolism: a rare cause of acute myocardial infarction. Rev Cardiovasc Med 2003; 4 (02) 107-111
    PubMedGoogle Scholar
  • 39 Ahmed S, Sadiq A, Siddiqui AK. , et al. Paradoxical arterial emboli causing acute limb ischemia in a patient with essential thrombocytosis. Am J Med Sci 2003; 326 (03) 156-158
    CrossrefPubMedGoogle Scholar
  • 40 Meier B, Kalesan B, Mattle HP. , et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013; 368 (12) 1083-1091
    CrossrefPubMedGoogle Scholar
  • 41 Wallentin L, Becker RC, Budaj A. , et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11) 1045-1057
    CrossrefPubMedGoogle Scholar
  • 42 Bonaca MP, Bhatt DL, Cohen M. , et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372 (19) 1791-1800
    CrossrefPubMedGoogle Scholar